Beyond Neddylation Inhibition: X-ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat

Pevonedistat (MLN4924) is a first-in-class inhibitor of the NEDD8-activating enzyme that blocks protein neddylation and exhibits antitumor activity in multiple clinical phases. Here, we report a previously unrecognized and isoform-selective inhibitory profile of pevonedistat against the tumor-associated isoforms human carbonic anhydrase IX and XII (hCA IX and XII). To elucidate the structural basis of this selectivity, X-ray crystal structures were determined for pevonedistat in complex with hCA I, hCA II, and an engineered hCA II variant mimicking hCA XII. These findings provide a mechanistic explanation for the known preferential partitioning of pevonedistat into whole blood via binding to erythrocyte CAs and suggest that CA inhibition may contribute to its antitumor activity in hypoxic tumor microenvironments where hCA IX and XII are overexpressed. This study reveals a dual functional profile for pevonedistat, linking neddylation inhibition with selective targeting of tumor-associated CAs and offers to exploit this synergy in anticancer drug design.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2026-05-27
DOI
https://doi.org/10.1021/acsmedchemlett.6c00197
Primary Topic
Enzyme function and inhibition
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond Neddylation Inhibition: X-ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat

Marta Ferraroni, Chiara Baroni, Claudiu T. Supuran, Andrea Angeli
ACS Medicinal Chemistry Letters
Enzyme function and inhibition
article

Beyond Neddylation Inhibition: X-ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat

Marta Ferraroni, Chiara Baroni, Claudiu T. Supuran, Andrea Angeli
article en

Abstract

Pevonedistat (MLN4924) is a first-in-class inhibitor of the NEDD8-activating enzyme that blocks protein neddylation and exhibits antitumor activity in multiple clinical phases. Here, we report a previously unrecognized and isoform-selective inhibitory profile of pevonedistat against the tumor-associated isoforms human carbonic anhydrase IX and XII (hCA IX and XII). To elucidate the structural basis of this selectivity, X-ray crystal structures were determined for pevonedistat in complex with hCA I, hCA II, and an engineered hCA II variant mimicking hCA XII. These findings provide a mechanistic explanation for the known preferential partitioning of pevonedistat into whole blood via binding to erythrocyte CAs and suggest that CA inhibition may contribute to its antitumor activity in hypoxic tumor microenvironments where hCA IX and XII are overexpressed. This study reveals a dual functional profile for pevonedistat, linking neddylation inhibition with selective targeting of tumor-associated CAs and offers to exploit this synergy in anticancer drug design.

ACS Medicinal Chemistry Letters
University of Florence (IT)
Openalex Percentile: Top 9%
Enzyme function and inhibition
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.